eli-002 2p
·Code: ELI-002 2P
eli-002 2p: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Elicio Therapeutics, Inc. (ELTX) | Phase 1 |
Clinical Trials (1)
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Frequently asked questions
Who is developing eli-002 2p?
eli-002 2p is being developed by Elicio Therapeutics, Inc..
How many clinical trials involve eli-002 2p?
BioSniper tracks 1 clinical trial involving eli-002 2p.
Get deeper analysis on eli-002 2p
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis